We also evaluated whether the peripheral humoral immune activation state in ALS patient was correlated with the duration, the disability level and the clinical subtype of the disease

We also evaluated whether the peripheral humoral immune activation state in ALS patient was correlated with the duration, the disability level and the clinical subtype of the disease. == Materials and Methods == == Subjects == After obtaining an Institutional Board Approval, serum IgG, IgM and IgA levels in 36 patients with definite or probable ALS were measured (19 men and 17 women, mean age 59.210.9 years) and 35 age-matched healthy subjects (20 men and 15 women, mean age 5611.6 years) used as control group. Patients with evidence of systemic inflammation on clinical examination or serum biochemical tests (increased number of white blood cells, high levels of C-reactive protein or erythrocyte sedimentation rate) were excluded. or spinal) were found in our ALS patients. Our results do not suggest a humoral immune activation in ALS patients. This does not exclude that immunological mechanisms may be involved in ALS pathogenesis. Key words:IgM, IgG, IgA, amyotrophic lateral sclerosis, humoral immune activation. == Introduction == Amyotrophic lateral sclerosis (ALS) is a devastating neurological disorder which affects upper and lower motoneurones leading to PCI-27483 muscle weakness and wasting, respiratory depression and death. A variety of immunological abnormalities have been reported in some patients with ALS. It has been postulated that a disturbance of immunoregulation may play a role in the degeneration of motor neurons in ALS. The results of various studies analyzing serum antibody levels are contradictory. Significant increases of serum IgG, but not IgM or IgA, have been found in ALS patients.1Besides, other reports demonstrated normal serum IgG, IgM, and IgA levels or normal IgG and high IgM levels in ALS patients at early disease stage.2,3In order to examine whether peripheral humoral immune activation is observed in ALS patients, we measured the serum immunoglobulins IgG, IgA and IgM concentrations in patients with ALS and normal controls. We also evaluated whether the peripheral PCI-27483 humoral immune activation state in ALS patient was correlated with the duration, the disability level and the clinical subtype of the disease. == Materials and Methods == == Subjects == After obtaining an Institutional Board Approval, serum IgG, IgM and IgA levels in 36 patients with definite or probable ALS were measured (19 men and 17 women, mean age 59.210.9 years) and 35 age-matched healthy subjects (20 men and 15 women, mean age 5611.6 years) used as control group. Patients with evidence of systemic inflammation on clinical examination or serum biochemical tests (increased number of white blood cells, high levels of C-reactive protein or erythrocyte sedimentation rate) were excluded. Patients with use of nonsteroidal anti-inflammatory drugs, acetylsalicylic acid, steroids or statins during the last two months before enrollment were also excluded from the study. All patients were submitted to appropriate blood tests to exclude ALS with Laboratory Abnormalities of Uncertain Significance (ALS-LAUS) Syndromes such as monoclonal gammopathy, auto-antibodies (high-titer GM1 ganglioside antibody), non-malignant endocrine abnormalities and infection (HIV-1, varicellazoster, syphilis, borrelliosis). In the ALS group, all patients met PCI-27483 the revised EI Escorial criteria for possible,4probable and definite ALS. Ten out of our patients with bulbar signs had bulbar onset. Duration of symptoms at the time of examination was 23.1732.7 months. The disability level associated with the development and progression of ALS was determined using PCI-27483 the revised ALS functional-rating scale (ALSFRS-R).5The ALS-FRS-R score was 40.36.5. Informed consent had been obtained by all patients for studying serum. Serum samples were stored at 70C until assayed. == Methods == Immunochemical determination of IgG, IgA and IgM serum levels was made with the use of Behring Nephelometer II (DADE BBEHRING, MARBURG GMBH). Serum samples were put in cuvettes along with the corresponding antiserum and the antigen-antibody complexes were formed. A light beam generated by means of an LED was scattered by the antigen-antibody complexes which were present and it was then Rabbit Polyclonal to eIF4B (phospho-Ser422) converted, by a detector, into an electrical signal proportional to the protein concentration in the measured sample. The final protein concentration was calculated with the use of a reference curve that had been made after several measurements of a standard with a known antigen concentration at different dilutions. The use of large latex particles led to the formation of large antigen-antibody complexes (>1000 nm) which, with the use of a smaller electromagnetic wave (840 nm), resulted in Mie scattering (the light was mainly scattered in the forward direction) and allowed improved light efficiency for the measurement. A prereaction test was incorporated into our protocol in order to exclude the possibility of samples with a very high antigen content giving false low results: PCI-27483 if positive, measurement was repeated automatically at the next dilution. == Statistical analysis == Data of patients and controls.